- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:34 | Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal | 15 | Zacks | ||
| 11:46 | AKTIEN IN FOKUS: Herzmittel-Flop drückt Novartis - Auch Ionis und Amgen schwach | 408 | dpa-AFX | ZÜRICH (dpa-AFX) - Der Misserfolg mit dem Herzmedikament Pelacarsen setzt am Montag gleich mehrere Aktien unter Druck. Zum einen die des Entwicklers Ionis Pharma und des Lizenznehmers Novartis und... ► Artikel lesen | |
| Fr | Wells Fargo raises Amgen stock price target to $435 on drug trial outlook | 35 | Investing.com | ||
| Fr | Wells Fargo hebt Amgen-Kursziel wegen Studienergebnissen auf 435 Dollar an | 56 | Investing.com Deutsch | ||
| Mi | Amgen slapped with U.K. suspension of rare-disorder therapy Tavneos | 20 | Seeking Alpha | ||
| 31.08. | 4 stocks to watch on Monday: AMGN, LLY, ARM, and MSTR | 11 | Seeking Alpha | ||
| AMGEN INC CDR Aktie jetzt für 0€ handeln | |||||
| 31.08. | How Is Amgen's Stock Performance Compared to Other General Drug Manufacturers | 3 | Barchart.com | ||
| 31.08. | Amgen's Repatha cuts death risk by 20% in heart study | 17 | Seeking Alpha | ||
| 31.08. | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | 411 | PR Newswire | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| 28.08. | Amgen, Astra post late-stage trial win for asthma drug Tezspire in swallowing disorder | 6 | Seeking Alpha | ||
| 27.08. | AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication | 7 | MedCity News | ||
| 27.08. | New data could widen use of AstraZeneca, Amgen immune disease drug | 14 | BioPharma Dive | ||
| 27.08. | Amgen, AstraZeneca's Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent | 11 | FiercePharma | ||
| 27.08. | AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study | 13 | Zacks | ||
| 27.08. | AZ, Amgen positive Ph3 results for Tezspire in EoE | 5 | pharmaphorum | ||
| 27.08. | AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease | 7 | Benzinga.com | ||
| 27.08. | AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial | 13 | Reuters | ||
| 27.08. | AstraZeneca and Amgen announce positive Tezspire trial results in EoE | 17 | Alliance News | ||
| 27.08. | Amgen und AstraZeneca: Positive Phase-3-Studienergebnisse für Tezspire bei eosinophiler Ösophagitis | 6 | Investing.com Deutsch | ||
| 27.08. | Amgen, AstraZeneca report positive phase 3 trial for Tezspire in EoE | 4 | Investing.com |
1 2 3 4 5 Weiter >>
265 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| QIAGEN | 36,340 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | ||
| PARABILIS MEDICINES | 40,420 | 0,00 % | Parabilis Medicines, Inc. - 8-K, Current Report |
Das Unternehmen AMGEN INC CDR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,300 (-1,49 %) liegt der Kurs bei 19,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC CDR finden Sie auf Wallstreet Online.